ImmunityBio Q3 net product revenue $48.7 million up 53%
ImmunityBio reported expanded FDA and global approvals for ANKTIVA and Q3 2026 revenue up 53% year-over-year, driven by strong market adoption despite generic competition.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed